Collagen V Oral Administration Decreases Inflammation And Remodeling Of Synovial Membrane In Experimental Arthritis

Because collagen type V (Col V) can be exposed in tissue injury, we hypothesized that oral administration of this collagen species modulates the inflammation and remodeling of experimental synovitis, avoiding joint destruction, and that the modulation may differ according to the temporal administration. Arthritis (IA, n = 20) was induced in Lewis rats by intraarticular (ia) injection of 500 mu g of methylated bovine serum albumin (mBSA) emulsified in complete Freund's adjuvant (CFA) (10 mu l) followed by an intraarticular booster of mBSA (50 mu g) in saline (50 mu l) administered at 7 and 14 days. The control group received saline (50 mu l, ia). After the first intraarticular injection, ten IA animals were supplemented via gavage with Col V (500 mu g/300 mu l) daily for 30 days (IA/Suppl). The control group received saline (50 mu L) and Col V supplement in the same way (Suppl). Col V oral administration in IA/Suppl led to 1) inhibited edema and severe inflammatory cell infiltration, 2) decreased collagen fiber content, 3) decreased collagen type I, 4) inhibited lymphocyte subpopulations and macrophages, 5) inhibited IL-1 beta, IL-10, IL-17 and TNF-alpha production and 6) increased expression of caspase-9 in the synovial tissue. In conclusion, Col V supplementation decreased synovial inflammation and the fibrotic response, possibly by increased the apoptosis of inflammatory cells.